Microchip battles retinitis pigmentosa

Article

Optobionics Corporation has announced positive interim results from a pilot clinical trial of its Artificial Silicon Retina (ASR) device, a treatment for retinitis pigmentosa.

Optobionics Corporation has announced positive interim results from a pilot clinical trial of its Artificial Silicon Retina (ASR) device, a treatment for retinitis pigmentosa.

A total of 20 patients were enrolled in a study to assess safety and to develop effective vision measures under an Investigational Device Exemption application approved by the FDA. At twelve months follow-up, of the ten subjects suffering with retinitits pigementosa, 40% attained a ten-letter improvement in visual acuity compared with a loss of vision for the untreated patients. No patient showed signs of implant rejection, infection, inflammation, erosion or retinal detachment related to the implanted device.

The ASR is a microchip designed to stimulate damaged retinal cells, allowing them to send visual signals again to the brain. As well as being a possible treatment option for retinitis pigmentosa, the manufacturers believe it could also be used to help treat age-related macular degeneration.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.